According to a new report published by Introspective Market Research, titled, Personalized Genomics Market by Test Type, Application, and End User, The Global Personalized Genomics Market Size Was Valued at USD 7.21 Billion in 2023 and is Projected to Reach USD 47.49 Billion by 2032, Growing at a CAGR of 23.30%. The global personalized genomics market is experiencing rapid growth, fueled by advancements in DNA sequencing technologies and the increasing demand for tailored healthcare solutions. Personalized genomics involves analyzing an individual’s genetic profile to provide customized insights into disease risks, drug response, lifestyle choices, and overall wellness. Unlike conventional diagnostics, this approach enables proactive health management and supports precision medicine strategies.
Key drivers include the decreasing cost of genome sequencing, greater awareness of preventive healthcare, and the expansion of direct-to-consumer genetic testing services. The integration of artificial intelligence and bioinformatics platforms is also enhancing genomic data interpretation, making results more accessible and actionable for both clinicians and consumers. With growing applications across oncology, pharmacogenomics, nutrition, ancestry, and lifestyle, the personalized genomics market is positioned as a transformative force in global healthcare.
The Personalized Genomics Market is segmented into Test Type, Application, and End User.
-
By Test Type, the market is categorized into Whole Genome Sequencing, Whole Exome Sequencing, Targeted Gene Sequencing, and Others.
-
By Application, the market is categorized into Oncology, Rare Diseases, Pharmacogenomics, Ancestry & Lifestyle, and Others.
-
By End User, the market is categorized into Hospitals & Clinics, Research Organizations, and Direct-to-Consumer.
A primary growth driver for the personalized genomics market is the increasing adoption of precision medicine. Genomic testing enables physicians to identify genetic variations influencing disease progression and treatment response, particularly in oncology. By providing tailored therapeutic solutions, personalized genomics significantly improves patient outcomes and minimizes trial-and-error prescriptions. As healthcare systems worldwide adopt precision medicine frameworks and governments fund genomics research, the adoption of personalized genomic testing is expected to accelerate rapidly.
The market presents significant opportunities in the direct-to-consumer (DTC) genomics space, where consumers can access genetic insights for wellness, ancestry, and lifestyle decisions without clinical mediation. Growing interest in personalized nutrition, fitness optimization, and preventive health is expanding the reach of consumer genomics companies. Additionally, the integration of genomic data into digital health platforms and wearable devices is opening new revenue streams. Companies leveraging AI-driven analytics and secure cloud-based platforms are poised to benefit most from this convergence of genomics and digital health.
Personalized Genomics Market, Segmentation
The Personalized Genomics Market is segmented on the basis of Test Type, Application, and End User.
Test Type
The Test Type segment is further classified into Whole Genome Sequencing, Whole Exome Sequencing, Targeted Gene Sequencing, and Others. Among these, the Whole Genome Sequencing sub-segment accounted for the highest market share in 2023. The segment’s dominance is attributed to its ability to provide comprehensive genetic information, which is increasingly used in disease risk prediction, pharmacogenomics, and consumer health services. Rapid technological advancements and cost reductions are expected to further strengthen this segment’s growth.
Application
The Application segment is further classified into Oncology, Rare Diseases, Pharmacogenomics, Ancestry & Lifestyle, and Others. Among these, the Oncology sub-segment accounted for the highest market share in 2023. Personalized genomics is revolutionizing cancer care by identifying tumor-specific mutations and guiding precision therapies. With the global burden of cancer rising, the demand for genomics-driven oncology solutions is expected to surge, supported by government initiatives and clinical research collaborations.
Some of The Leading/Active Market Players Are-
- Illumina, Inc. (USA)
- Thermo Fisher Scientific Inc. (USA)
- F. Hoffmann-La Roche AG (Switzerland)
- BGI Genomics Co., Ltd. (China)
- 23andMe, Inc. (USA)
- Myriad Genetics, Inc. (USA)
- Gene by Gene, Ltd. (USA)
- Color Health, Inc. (USA)
- Dante Labs (Italy)
- QIAGEN N.V. (Netherlands/Germany)
- Nebula Genomics (USA)
- Veritas Genetics (USA)
- Mapmygenome India Ltd. (India)
- Oxford Nanopore Technologies plc (UK)
- Invitae Corporation (USA)
- other active players.
Key Industry Developments
- In April 2024, Illumina announced a partnership with a global healthcare network to integrate genomic testing into oncology care pathways.
This collaboration aims to enhance access to precision medicine and accelerate the adoption of genomic testing for cancer treatment worldwide. - In September 2024, 23andMe expanded its wellness portfolio by launching AI-driven genomic insights for nutrition and fitness.
This expansion reflects the company’s strategic shift toward consumer wellness and its commitment to broadening the scope of personalized genomics beyond ancestry testing.
Key Findings of the Study
- Whole Genome Sequencing dominated the test type segment in 2023.
- Oncology was the leading application area.
- North America accounted for the largest share of the global market.
- Precision medicine initiatives are driving market expansion.
- DTC genomics and digital health integration present major opportunities.
